CLINICAL_TRIALS
trial_result
· 2024-06-10
Clinical Trial Update: Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants [Phase 1]
Summary
A Phase 1 trial in healthy adults evaluated the safety, tolerability, and immunogenicity of VAL-181388 for chikungunya. The study results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ModernaTX, Inc. | Conditions: Chikungunya Virus | Phase 1 | Status: COMPLETED | Results posted: 2024-06-10